US2011313016A1PendingUtilityA1

Treatment of Intestinal Conditions

54
Individually held — no corporate assignee on recordPriority: Mar 14, 2005Filed: Mar 14, 2006Published: Dec 22, 2011
Est. expiryMar 14, 2025(expired)· nominal 20-yr term from priority
Inventors:Ana I. JiménezIrene GascónMaria JimenezJosé P. RománÁngela Sesto
A61P 37/02A61P 37/06A61P 3/10A61P 37/00A61P 35/04A61P 43/00A61P 31/00A61P 25/00A61P 31/04A61P 33/04A61P 29/00A61P 35/00A61P 1/00A61P 1/10A61P 1/04A61P 1/14A61P 1/12A61K 31/7115A61K 31/00Y02A50/30
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compositions for the treatment of intestinal disorders, such as IBD and Crohn's disease, are disclosed. Preferred compositions include siNA. Also disclosed is a method of specifically targeting siNA to treat intestinal disorders by intrarectal administration of siNA compounds.

Claims

exact text as granted — not AI-modified
1 - 47 . (canceled) 
     
     
         48 . A method of treating an intestinal disorder in an individual, comprising administering to a patient a therapeutically effective amount of a short interfering nucleic acid molecule (siNA), wherein the siNA molecule targets Interleukin 12. 
     
     
         49 . The method according to  claim 48 , wherein the siNA molecule is administered intrarectally. 
     
     
         50 . The method of  claim 48 , wherein the disorder is localized in an organ selected from the group consisting of the small intestine, the large intestine, and the rectum. 
     
     
         51 . The method of  claim 48 , wherein the disorder is a disorder of the small intestine. 
     
     
         52 . The method of  claim 48 , wherein the disorder is selected from the group consisting of hyperproliferative diseases, autoimmune and inflammatory bowel diseases (IBD), infectious diseases of the intestine, malabsorption syndromes, rectal diseases and diarrhea. 
     
     
         53 . The method of  claim 48 , wherein the disorder is selected from the group consisting of colorectal cancer, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, pseudomembranous colitis, amebiasis, intestinal tuberculosis, colonic polyps, diverticular disease, constipation, and intestinal obstruction. 
     
     
         54 . The method of  claim 48 , wherein the siNA molecule is selected from the group consisting of dsRNA, siRNA, and shRNA. 
     
     
         55 . The method of  claim 48 , wherein the siNA molecule is dsRNA. 
     
     
         56 . The method of  claim 48 , wherein the siNA molecule modulates miRNA levels. 
     
     
         57 . The method of  claim 48 , wherein the siNA molecule comprises a modified oligonucleotide. 
     
     
         58 . The method of  claim 48 , wherein the siNA molecule is 40 base pairs or fewer in length. 
     
     
         59 . The method of  claim 48 , wherein the siNA molecule has 3′ overhangs. 
     
     
         60 . The method of  claim 59 , wherein the 3′ overhangs are dinucleotides. 
     
     
         61 . The method of  claim 60 , wherein the dinucleotide overhangs are made of thymidine nucleotides. 
     
     
         62 . The method of  claim 48 , wherein a plurality of siNA molecules is used, and wherein the siNA molecules are targeted to the same mRNA sequences or to different mRNA sequences. 
     
     
         63 . The method of  claim 48 , wherein the siNA molecule comprises a sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 85. 
     
     
         64 . The method of  claim 48 , wherein the siNA molecule is targeted to the Interleukin-12 35 kDa subunit (IL12-p35). 
     
     
         65 . The method of  claim 64 , wherein the siNA molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 33. 
     
     
         66 . The method of  claim 48 , wherein the siNA molecule is targeted to the Interleukin-12 40 kDa subunit (IL12-p40). 
     
     
         67 . The method of  claim 66 , wherein the siNA molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 34 to SEQ ID NO: 85. 
     
     
         68 . A method of treating an intestinal disorder in an individual, comprising administering intrarectally to a patient a therapeutically effective amount of a short interfering nucleic acid molecule (siNA) that targets a gene associated with said intestinal disorder. 
     
     
         69 . The method of  claim 68 , wherein the disorder is selected from the group consisting of hyperproliferative diseases, autoimmune and inflammatory bowel diseases (IBD), infectious diseases of the intestine, malabsorption syndromes, rectal diseases and diarrhea. 
     
     
         70 . The method of  claim 68 , wherein the disorder is selected from the group consisting of colorectal cancer, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, pseudomembranous colitis, amebiasis, intestinal tuberculosis, colonic polyps, diverticular disease, constipation, and intestinal obstruction. 
     
     
         71 . A pharmaceutical composition for the treatment of an intestinal disorder comprising a short interfering nucleic acid molecule (siNA) compound formulated for intrarectal administration. 
     
     
         72 . The pharmaceutical composition of  claim 71 , wherein the siNA molecule targets IL-12 mRNA expression. 
     
     
         73 . The pharmaceutical composition of  claim 72 , wherein the siNA molecule comprises a sequence selected from SEQ ID NO: 1 to SEQ ID NO: 85.

Join the waitlist — get patent alerts

Track US2011313016A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.